Cherry Thomas

Cherry joined Catamaran as Chief Medical Officer in April 2022. She has extensive pharmaceutical and biotech industry experience and expertise in the clinical development of oncology therapeutics, including allogeneic cell therapies. Prior to joining Catamaran, Cherry was senior vice president of clinical development at Caribou Biosciences. She initiated and built Caribou’s clinical development program and advanced the company’s first allogeneic CAR-T cell therapy into the clinic. Prior to this role, Cherry held positions of increasing responsibility and leadership in U.S. and global clinical development and medical affairs, including at Array Biopharma/Pfizer, Bristol Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. Cherry completed her residency in radiation oncology at the University of Michigan and is a licensed physician and surgeon. She holds an MD from the University of California, Irvine and a BA from the University of California, Los Angeles.